Immune Regulation — Enzo Therapeutics
Immune Regulation
Proprietary immunomodulatory platforms for precision control of immune responses. Our clinical-stage programs Alequel® and Optiquel® target autoimmune diseases and transplant rejection through novel tolerance-induction mechanisms.
Precision Immunomodulation for Unmet Medical Needs
Enzo’s immune regulation platform represents decades of immunology expertise translated into clinical therapeutic programs. Rather than broadly suppressing the immune system — the approach used by conventional immunosuppressants — our proprietary technologies modulate specific immune pathways to restore tolerance while preserving protective immunity. This precision approach reduces side effects and enables long-term disease management for patients with autoimmune conditions and organ transplant recipients.
Alequel® — Oral Tolerization
Alequel is Enzo’s proprietary oral tolerization platform designed to induce antigen-specific immune tolerance through the gut-associated lymphoid tissue (GALT). By delivering disease-relevant autoantigens via the oral route, Alequel stimulates regulatory T-cell responses that suppress pathological autoimmunity without global immunosuppression. Clinical development targets include rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.
Optiquel® — Transplant Tolerance
Optiquel is a novel immunomodulatory approach for preventing organ transplant rejection. By inducing donor-specific immune tolerance, Optiquel aims to eliminate the need for lifelong immunosuppressive therapy following solid organ transplantation. Preclinical studies have demonstrated prolonged graft survival with preserved immune competence against infections and malignancies.
Checkpoint Modulation
Novel small molecules and biologics targeting immune checkpoint pathways including PD-1/PD-L1, CTLA-4, and LAG-3. Enzo’s proprietary compound libraries and screening platforms enable the discovery of differentiated checkpoint modulators for cancer immunotherapy and autoimmune disease management.
Cytokine & T-Cell Engineering
Proprietary approaches to modulating cytokine signaling cascades (TNF-α, IL-6, IL-17, interferons) combined with technologies supporting adoptive cell therapy, including T-cell activation, expansion, and characterization tools for CAR-T and TCR-T therapeutic development.
Immune Regulation — By the Numbers
Partner on Our Immune Regulation Programs
Connect with our business development team to explore licensing, co-development, and technology transfer opportunities across our therapeutic platforms.